The interleukin-1 families of cytokines and receptors: therapeutic potential for immunomodulation and the treatment of inflammatory disorders

Bibliography

• DINARELLO CA: Biologic basis for interleukin-1 in disease. Blood (1996) 87:2095-2147.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: Interleukin-1. Cytokine Growth Factor Rev. (1997) 8:253-265.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: Proinflammatory cytokines. Chest (2000) 118:503-508.
   PubMed Web of Science ®Google Scholar
• AREND WP, MALYAK M, GUTHRIDGE CJ, GABAY C: Interleukin-1 receptor antagonist: role in biology. Ann. Rev. Immunol. (1998) 16:27-55.
   PubMed Web of Science ®Google Scholar
• AREND WP: The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. (2002) 13:323-340.
   PubMed Web of Science ®Google Scholar
• NICKLIN MJ, BARTON JL, NGUYEN M et al.: A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics (2002) 79:718-725.
   PubMed Web of Science ®Google Scholar
• GRACIE JA, ROBERTSON SE, MCINNES IB: Interleukin-18. J. Leukoc. Biol. (2003) 73:213-224.
   PubMed Web of Science ®Google Scholar
• MUHL H, PFEILSCHIFTER J: Interleukin-18 bioactivity: a novel target for imunopharmacological anti-inflammatory intervention. Eur. J. Pharmacol. (2004) 500:63-71.
   PubMed Web of Science ®Google Scholar
• DUNN E, SIMS JE, NICKLIN MJ, O’NEILL LA: Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol. (2001) 22:533-536.
   PubMed Web of Science ®Google Scholar
• SIMS JE, NICKLIN MJ, BAZAN JF et al.: A new nomenclature for IL-1-family genes. Trends Immunol. (2001) 22:536-537.
   PubMed Web of Science ®Google Scholar
• SCHMITZ J, OWYANG A, OLDHAM E et al.: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper Type 2-associated cytokines. Immunity (2005) 23:479-490.
   PubMed Web of Science ®Google Scholar
• SIMS JE: IL-1 and IL-18 receptors, and their extended family. Curr. Opin. Immunol. (2002) 14:117-122.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAM S, STANSBERG C, CUNNINGHAM C: The interleukin 1 receptor family. Dev. Comp. Immunol. (2004) 28:415-428.
   PubMed Web of Science ®Google Scholar
• LI X, QIN J: Modulation of Toll-interleukin 1 receptor mediated signaling. J. Mol. Med. (2005) 83:258-266.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. (2002) 20:S10-S13.
   Google Scholar
• KORNMAN KS: Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am. J. Clin. Nutr. (2006) 83:475S-483S.
   PubMed Web of Science ®Google Scholar
• DUFF GW: Evidence for genetic variation as a factor in maintaining health. Am. J. Clin. Nutr. (2006) 83:431S-435S.
   PubMed Web of Science ®Google Scholar
• FURST DE: Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin. Ther. (2004) 26:1960-1975.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: Blocking IL-1 in systemic inflammation. J. Exp. Med. (2005) 201:1355-1359.
   PubMed Web of Science ®Google Scholar
• BRADDOCK M, QUINN A: Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discovery (2004) 3:330-339.
   PubMed Web of Science ®Google Scholar
• BRADDOCK M, QUINN A, CANVIN J: Therapeutic potential of targeting IL-1 and IL-18 in inflammation. Expert Opin. Biol. Ther. (2004) 4:847-860.
   PubMed Web of Science ®Google Scholar
• BURYSKOVA M, POSPISEK M, GROTHEY A, SIMMET T, BURYSEK L: Intracellular interleukin-1α functionally interacts with histone acetyltransferase complexes. J. Biol. Chem. (2004) 279:4017-4026.
   PubMed Web of Science ®Google Scholar
• WERMAN A, WERMAN-VENKERT R, WHITE R et al.: The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc. Natl. Acad. Sci. USA (2004) 101:2434-2439.
   PubMed Web of Science ®Google Scholar
• PALMER G, TROLLIET S, TALABOT-AYER D et al.: Pre-interleukin-1α expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1). Cytokine (2005) 31:153-160.
   PubMed Web of Science ®Google Scholar
• NIKI Y, YAMADA H, KIKUCHI T et al.: Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 α transgenic mice. J. Immunol. (2004) 172:577-584.
   PubMed Web of Science ®Google Scholar
• ZALDIVAR F, NUGENT DJ, IMFELD K, BERMAN MA: Identification of a novel regulatory element in the human interleukin 1 α (IL-1α) gene promoter. Cytokine (2002) 20:130-135.
   PubMed Web of Science ®Google Scholar
• MCDOWELL TL, SYMONS JA, DUFF GW: Human interleukin-1α gene expression is regulated by Sp1 and a transcriptional repressor. Cytokine (2005) 30:141-153.
   PubMed Web of Science ®Google Scholar
• RANDLE JC, HARDING MW, KU G, SCHONHARTING M, KURRLE R: ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin. Investig. Drugs (2001) 10:1207-1209.
   PubMed Web of Science ®Google Scholar
• HERZOG C, KAUSHAL GP, HAUN RS: Generation of biologically active interleukin-1β by meprin B. Cytokine (2005) 31:394-403.
   PubMed Web of Science ®Google Scholar
• BURNS K, MARTINON F, TSCHOPP J: New insights into the mechanism of IL-1β maturation. Curr. Opin. Immunol. (2003) 15:26-30.
   PubMed Web of Science ®Google Scholar
• MARTINON F, TSCHOPP J: Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell (2004) 117:561-574.
   PubMed Web of Science ®Google Scholar
• STEHLIK C, LEE SH, DORFLEUTNER A et al.: Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J. Immunol. (2003) 171:6154-6163.
   PubMed Web of Science ®Google Scholar
• YU JW, WU J, ZHANG Z et al.: Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Differ (2006) 13:236-249.
   PubMed Web of Science ®Google Scholar
• MARIATHASAN S, WEISS DS, NEWTON K et al.: Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 440:228-232.
   PubMed Web of Science ®Google Scholar
• KANNEGANTI TD, OZOREN N, BODY-MALAPEL M et al.: Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 440:233-236.
   PubMed Web of Science ®Google Scholar
• MARTINON F, PETRILLI V, MAYOR A, TARDIVEL A, TSCHOPP J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 440:237-241.
   PubMed Web of Science ®Google Scholar
• AGOSTINI L, MARTINON F, BURNS K et al.: NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 20:319-325.
   PubMed Web of Science ®Google Scholar
• STOJANOV S, KASTNER DL: Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr. Opin. Rheumatol. (2005) 17:586-599.
   PubMed Web of Science ®Google Scholar
• SOLLE M, LABASI J, PERREGAUX DG et al.: Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem. (2001) 276:125-132.
   PubMed Web of Science ®Google Scholar
• SLUYTER R, SHEMON AN, WILEY JS: Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1β release from human monocytes. 2004 (2004) 172:3399-3405.
   Google Scholar
• BROUGH D, LE FEUVRE RA, WHEELER RD et al.: Ca2+ stores and Ca2+ entry differentially contribute to the release of IL-1 β and IL-1 α from murine macrophages. J. Immunol. (2003) 170:3029-3036.
   PubMed Web of Science ®Google Scholar
• KAHLENBERG JM, DUBYAK GR: Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am. J. Physiol. Cell Physiol. (2004) 286:C1100-C1108.
   PubMed Web of Science ®Google Scholar
• ANDREI C, MARGIOCCO P, POGGI A et al.: Phospholipases C and A2 control lysosome-mediated IL-1 β secretion: Implications for inflammatory processes. Proc. Natl. Acad. Sci. USA (2004) 101:9745-9750.
   PubMed Web of Science ®Google Scholar
• KAHLENBERG JM, LUNDBERG KC, KERTESY SB, QU Y, DUBYAK GR: Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-κB-driven protein synthesis. J. Immunol. (2005) 175:7611-7622.
   PubMed Web of Science ®Google Scholar
• VERHOEF PA, KERTESY SB, LUNDBERG K, KAHLENBERG JM, DUBYAK GR: Inhibitory effects of chloride on the activation of caspase-1, IL-1 secretion, and cytolysis by the P2X7 receptor. J. Immunol. (2005) 175:7623-7634.
   PubMed Web of Science ®Google Scholar
• ELSSNER A, DUNCAN M, GAVRILIN M, WEWERS MD: A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 β processing and release. J. Immunol. (2004) 172:4987-4994.
   PubMed Web of Science ®Google Scholar
• JOOSTEN LA, NETEA MG, KIM SH et al.: IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA (2006) 103:3298-3303.
   PubMed Web of Science ®Google Scholar
• NETEA MG, AZAM T, FERWERDA G et al.: IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1β and IL-6 production through a caspase 1-dependent mechanism. Proc. Natl. Acad. Sci. USA (2005) 102:16309-16314.
   PubMed Web of Science ®Google Scholar
• KHORUTS A, OSNESS RE, JENKINS MK: IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands. Eur. J. Immunol. (2004) 34:1085-1090.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-ALAVEZ M, TABAREAN IV, BEHRENS MM, BARTFAI T: Ceramide mediates the rapid phase of febrile response to IL-1β. Proc. Natl. Acad. Sci. USA (2006) 103:2904-2908.
   PubMed Web of Science ®Google Scholar
• BAKER FC, SHAH S, STEWART D et al.: Interleukin 1β enhances non-rapid eye movement sleep and increases c-Fos protein expression in the median preoptic nucleus of the hypothalamus. Am. J. Physiol. Reg. Integr. Comp. Physiol. (2005) 288:R998-R1005.
   Google Scholar
• BAJAYO A, GOSHEN I, FELDMAN S et al.: Central IL-1 receptor signaling regulates bone growth and mass. Proc. Natl. Acad. Sci. USA (2005) 102:12956-12961.
   PubMed Web of Science ®Google Scholar
• WEI S, KITAURA H, ZHOU P, ROSS FP, TEITELBAUM SL: IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. (2005) 115:282-290.
   PubMed Web of Science ®Google Scholar
• GOSHEN I, YIRMIYA R, IVERFELDT K, WEIDENFELD J: The role of endogenous interleukin-1 in stress-induced adrenal activation and adrenalectomy-induced adrenocorticotropic hormone hypersecretion. Endocrinology (2003) 144:4453-4458.
   PubMed Web of Science ®Google Scholar
• MATSUKI T, HORAI R, SUDO K, IWAKURA Y: IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. (2003) 198:877-888.
   PubMed Web of Science ®Google Scholar
• SOMM E, CETTOUR-ROSE P, ASENSIO C et al.: Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia (2006) 49:387-393.
   PubMed Web of Science ®Google Scholar
• IWAKURA Y: Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. (2002) 13:341-355.
   PubMed Web of Science ®Google Scholar
• BASU A, KRADY JK, LEVISON SW: Interleukin-1: a master regulator of neuroinflammation. J. Neurosci. Res. (2004) 78:151-156.
   PubMed Web of Science ®Google Scholar
• ALLAN SM, TYRRELL PJ, ROTHWELL NJ: Interleukin-1 and neuronal injury. Nat. Rev. Immunol. (2005) 5:629-640.
   PubMed Web of Science ®Google Scholar
• SECKINGER P, LOWENTHAL JW, WILLIAMSON K, DAYER JM, MACDONALD HR: A urine inhibitor of interleukin 1 activity that blocks ligand binding. J. Immunol. (1987) 139:1546-1549.
   PubMed Web of Science ®Google Scholar
• EISENBERG SP, EVANS RJ, AREND WP et al.: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature (1990) 343:341-346.
   PubMed Web of Science ®Google Scholar
• WILSON HL, FRANCIS SE, DOWER SK, CROSSMAN DC: Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. J. Immunol. (2004) 173:1202-1208.
   PubMed Web of Science ®Google Scholar
• GARAT C, AREND WP: Intracellular IL-1Ra Type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-κB pathways. Cytokine (2003) 23:31-40.
   PubMed Web of Science ®Google Scholar
• BANDA NK, GUTHRIDGE C, SHEPPARD D et al.: Intracellular IL-1 receptor antagonist Type 1 inhibits IL-1-induced cytokine production in keratinocytes through binding to the third component of the COP9 signalosome. J. Immunol. (2005) 174:3608-3616.
   PubMed Web of Science ®Google Scholar
• MERHI-SOUSSI F, BERTI M, WEHRLE-HALLER B, GABAY C: Intracellular interleukin-1 receptor antagonist Type 1 antagonizes the stimulatory effect of interleukin-1α precursor on cell motility. Cytokine (2005) 32:163-170.
   PubMed Web of Science ®Google Scholar
• SCHRODER AK, VON DER OHE M, FLEISCHER D, RINK L, UCIECHOWSKI P: Differential synthesis of two interleukin-1 receptor antagonist variants and interleukin-8 by peripheral blood neutrophils. Cytokine (2005) 32:246-253.
   PubMed Web of Science ®Google Scholar
• KIM SH, AZAM T, NOVICK D et al.: Identification of amino acid residues critical for biological activity in human interleukin-18. J. Biol. Chem. (2002) 277:10998-11003.
   PubMed Web of Science ®Google Scholar
• SLUYTER R, DALITZ JG, WILEY JS: P2X7 receptor polymorphism impairs extracellular adenosine 5′-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun. (2004) 5:588-591.
   PubMed Web of Science ®Google Scholar
• SUGAWARA S, UEHARA A, NOCHI T et al.: Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. (2001) 167:6568-6575.
   PubMed Web of Science ®Google Scholar
• NIYONSABA F, USHIO H, NAGAOKA I, OKUMURA K, OGAWA H: The human β-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J. Immunol. (2005) 175:1776-1784.
   PubMed Web of Science ®Google Scholar
• BUFLER P, GAMBONI-ROBERTSON F, AZAM T, KIM SH, DINARELLO CA: Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem. J. (2004) 381:503-510.
   PubMed Web of Science ®Google Scholar
• SEKIYAMA A, UEDA H, KASHIWAMURA S et al.: A stress-induced, superoxide-mediated caspase-1 activation pathway causes plasma IL-18 upregulation. Immunity (2005) 22:669-677.
   PubMed Web of Science ®Google Scholar
• NAKANISHI K, YOSHIMOTO T, TSUTSUI H, OKAMURA H: Interleukin-18 regulates both TH1 and TH2 responses. Ann. Rev. Immunol. (2001) 19:423-474.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO T, ISHIKAWA Y, YOSHIMOTO T et al.: Interleukin 18 acts on memory T helper cells Type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J. Exp. Med. (2004) 199:535-545.
   PubMed Web of Science ®Google Scholar
• DAI SM, MATSUNO H, NAKAMURA H, NISHIOKA K, YUDOH K: Interleukin-18 enhances monocyte tumor necrosis factor α and interleukin-1β production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum. (2004) 50:432-443.
   PubMed Web of Science ®Google Scholar
• JOOSTEN LA, SMEETS RL, KOENDERS MI et al.: Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am. J. Pathol. (2004) 165:959-967.
   PubMed Web of Science ®Google Scholar
• HORWOOD NJ, ELLIOTT J, MARTIN TJ, GILLESPIE MT: IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. (2001) 166:4915-4921.
   PubMed Web of Science ®Google Scholar
• DAI SM, NISHIOKA K, YUDOH K: Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 β and tumour necrosis factor α. Ann. Rheum. Dis. (2004) 63:1379-1386.
   PubMed Web of Science ®Google Scholar
• SEKIYAMA A, UEDA H, KASHIWAMURA S et al.: A role of the adrenal gland in stress-induced up-regulation of cytokines in plasma. J. Neuroimmunol. (2006) 171:38-44.
   PubMed Web of Science ®Google Scholar
• SMITH DE, RENSHAW BR, KETCHEM RR et al.: Four new members expand the interleukin-1 superfamily. J. Biol. Chem. (2000) 275:1169-1175.
   PubMed Web of Science ®Google Scholar
• BUSFIELD SJ, COMRACK CA, YU G et al.: Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics (2000) 66:213-216.
   PubMed Web of Science ®Google Scholar
• MULERO JJ, NELKEN ST, FORD JE: Organization of the human interleukin-1 receptor antagonist gene IL1HY1. Immunogenetics (2000) 51:425-428.
   PubMed Web of Science ®Google Scholar
• DEBETS R, TIMANS JC, HOMEY B et al.: Two novel IL-1 family members, IL-1δ and IL-1ε, function as an antagonist and agonist of NF-κB activation through the orphan IL-1 receptor-related protein 2. J. Immunol. (2001) 167:1440-1446.
   PubMed Web of Science ®Google Scholar
• BARTON JL, HERBST R, BOSISIO D, HIGGINS L, NICKLIN MJ: A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities. Eur. J. Immunol. (2000) 30:3299-3308.
   PubMed Web of Science ®Google Scholar
• DUNN EF, GAY NJ, BRISTOW AF et al.: High-resolution structure of murine interleukin 1 homologue IL-1F5 reveals unique loop conformations for receptor binding specificity. Biochemistry (2003) 42:10938-10944.
   PubMed Web of Science ®Google Scholar
• TOWNE JE, GARKA KE, RENSHAW BR, VIRCA GD, SIMS JE: Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-κB and MAPKs. J. Biol. Chem. (2004) 279:13677-13688.
   PubMed Web of Science ®Google Scholar
• KUMAR S, HANNING CR, BRIGHAM-BURKE MR et al.: Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production. Cytokine (2002) 2002:61-71.
   Google Scholar
• PAN G, RISSER P, MAO W et al.: IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine (2001) 13:1-7.
   PubMed Web of Science ®Google Scholar
• TAYLOR SL, RENSHAW BR, GARKA KE, SMITH DE, SIMS JE: Genomic organization of the interleukin-1 locus. Genomics (2002) 79:726-733.
   PubMed Web of Science ®Google Scholar
• BUFLER P, AZAM T, GAMBONI-ROBERTSON F et al.: A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. USA (2002) 99:13723-13728.
   PubMed Web of Science ®Google Scholar
• GAO W, KUMAR S, LOTZE MT et al.: Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J. Immunol. (2003) 170:107-113.
   PubMed Web of Science ®Google Scholar
• WANG P, MEINHARDT B, ANDRE R et al.: The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1β signalling responses. Cytokine (2005) 29:245-250.
   PubMed Web of Science ®Google Scholar
• KUMAR S, MCDONNELL PC, LEHR R et al.: Identification and initial characterization of four novel members of the interleukin-1 family. J. Biol. Chem. (2000) 275:10308-10314.
   PubMed Web of Science ®Google Scholar
• BERGLOF E, ANDRE R, RENSHAW BR et al.: IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J. Neuroimmunol. (2003) 139:36-43.
   PubMed Web of Science ®Google Scholar
• LIN H, HO AS, HALEY-VICENTE D et al.: Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J. Biol. Chem. (2001) 276:20597-20602.
   PubMed Web of Science ®Google Scholar
• BENSEN JT, DAWSON PA, MYCHALECKYJ JC, BOWDEN DW: Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J. Interferon Cytokine Res. (2001) 21:899-904.
   PubMed Web of Science ®Google Scholar
• CASADIO R, FRIGIMELICA E, BOSSU P et al.: Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/IL-1R(I) complex. FEBS Lett. (2001) 499:65-68.
   PubMed Web of Science ®Google Scholar
• VIGERS GP, DRIPPS DJ, EDWARDS CK, BRANDHUBER BJ: X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor Type 1. J. Biol. Chem. (2000) 275:36927-36933.
   PubMed Web of Science ®Google Scholar
• JENSEN LE, MUZIO M, MANTOVANI A, WHITEHEAD AS: IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J. Immunol. (2000) 164:5277-5286.
   PubMed Web of Science ®Google Scholar
• SMITH DE, HANNA R, FRIEND D et al.: The soluble form of IL-1 receptor accessory protein enhances the ability of soluble Type II IL-1 receptor to inhibit IL-1 action. Immunity (2003) 18:87-96.
   PubMed Web of Science ®Google Scholar
• JENSEN LE, WHITEHEAD AS: Expression of alternatively spliced interleukin-1 receptor accessory protein mRNAs is differentially regulated during inflammation and apoptosis. Cell. Signal. (2003) 15:793-802.
   PubMed Web of Science ®Google Scholar
• DUNNE A, O’NEILL LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE (2003) 171:re3.
   Google Scholar
• JANSSENS S, BEYAERT R: Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell (2003) 11:293-302.
   PubMed Web of Science ®Google Scholar
• LI S, STRELOW A, FOMTANA EJ, WESCHE H: IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc. Natl. Acad. Sci. USA (2002) 99:5567-5572.
   PubMed Web of Science ®Google Scholar
• DIDIERLAURENT A, BRISSONI B, VELIN D et al.: Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell. Biol. (2006) 26:735-742.
   PubMed Web of Science ®Google Scholar
• JIANG Z, JOHNSON HJ, NIE H et al.: Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through its interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 6 (TRAF6) complex. J. Biol. Chem. (2003) 278:10952-10956.
   PubMed Web of Science ®Google Scholar
• FUNAKOSHI-TAGO M, TAGO K, ANDOH K et al.: Functional role of c-Src in IL-1-induced NF-κ B activation: c-Src is a component of the IKK complex. J. Biochem. (2005) 137:189-197.
   PubMed Web of Science ®Google Scholar
• JALAL DI, KONE BC: Src activation of NF-κB augments IL-1β-induced nitric oxide production in mesangial cells. J. Am. Soc. Nephrol. (2006) 17:99-106.
   PubMed Web of Science ®Google Scholar
• DAVIS CN, MANN E, BEHRENS MM et al.: MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc. Natl. Acad. Sci. USA (2006) 103:2953-2958.
   PubMed Web of Science ®Google Scholar
• NEUMANN D, KOLLEWE C, MARTIN MU, BORASCHI D: The membrane form of the Type II IL-1 receptor accounts for inhibitory function. J. Immunol. (2000) 165:3350-3357.
   PubMed Web of Science ®Google Scholar
• BOURKE E, CASSETTI A, VILLA A et al.: IL-1 β scavenging by the Type II IL-1 decoy receptor in human neutrophils. J. Immunol. (2003) 170:5999-6005.
   PubMed Web of Science ®Google Scholar
• WANG J, ELEWAUT D, VEYS EM, VERBRUGGEN G: Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the activity of interleukin-1 and controls the homeostasis of the extracellular matrix of cartilage. Arthritis Rheum. (2003) 48:1281-1291.
   PubMed Web of Science ®Google Scholar
• MANTOVANI A, LOCATI M, V ECCHI A, SOZZANI S, ALLAVENA P: Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. (2001) 22:328-336.
   PubMed Web of Science ®Google Scholar
• CUI X, ROUHANI FN, HAWARI F, LEVINE SJ: Shedding of the Type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor Type 1 shedding. J. Immunol. (2003) 171:6814-6819.
   PubMed Web of Science ®Google Scholar
• DEBETS R, TIMANS JC, CHURAKOWA T et al.: IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J. Immunol. (2000) 165:4950-4956.
   PubMed Web of Science ®Google Scholar
• CHEUNG H, CHEN NJ, CAO Z et al.: Accessory protein-like is essential for IL-18-mediated signaling. J. Immunol. (2005) 174:5351-5357.
   PubMed Web of Science ®Google Scholar
• VERMOT-DESROCHES C, UBIGER O, GUENOT F et al.: Monoclonal antibodies specific for the IL-18 receptor. Cell. Immunol. (2005) 236:86-91.
   PubMed Web of Science ®Google Scholar
• KATO Z, JEE J, SHIKANO H et al.: The structure and binding mode of interleukin-18. Nat. Struct. Biol .(2003) 10:966-971.
   PubMedGoogle Scholar
• AZAM T, NOVICK D, BUFLER P et al.: Identification of a critical Ig-like domain in IL-18 receptor α and characterization of a functional IL-18 receptor complex. J. Immunol. (2003) 171:6574-6580.
   PubMed Web of Science ®Google Scholar
• KIM SH, AZAM T, YOON DY et al.: Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein. Proc. Natl. Acad. Sci. USA (2001) 98:3304-3309.
   PubMed Web of Science ®Google Scholar
• BORN TL, THOMASSEN E, BIRD TA, E SJ: Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J. Biol. Chem. (1998) 23:29445-29450.
   Google Scholar
• WU C, SAKORAFAS P, MILLER R et al.: IL-18 receptor β-induced changes in the presentation of IL-18 binding sites affect ligand binding and signal transduction. J. Immunol. (2003) 170:5571-5577.
   PubMed Web of Science ®Google Scholar
• KUNIKATA T, TORIGOE K, USHIO S et al.: Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody. Cell. Immunol. (1998) 189:135-143.
   PubMed Web of Science ®Google Scholar
• CHAN WL, PEJNOVIC N, LEE CA, AL-ALI NA: Human IL-18 receptor and ST2L are stable and selective markers for the respective Type 1 and Type 2 circulating lymphocytes. J. Immunol. (2001) 167:1238-1244.
   PubMed Web of Science ®Google Scholar
• GUTZMER R, LANGER K, MOMMERT S et al.: Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J. Immunol. (2003) 171:6363-6371.
   PubMed Web of Science ®Google Scholar
• SARENEVA T, JULKUNEN I, MATIKAINEN S: IFN-α and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J. Immunol. (2000) 165:1933-1938.
   PubMed Web of Science ®Google Scholar
• THOMASSEN E, BIRD TA, RENSHAW BR, KENNEDY MK, SIMS JE: Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J. Interferon Cytokine Res. (1998) 18:1077-1088.
   PubMed Web of Science ®Google Scholar
• MOREL JCM, PARK CC, ZHU K et al.: Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J. Biol. Chem. (2002) 277:34679-34691.
   PubMed Web of Science ®Google Scholar
• LEE JK, KIM SH, LEWIS EC et al.: Differences in signaling pathways by IL-1β and IL-18. Proc. Natl. Acad. Sci. USA (2004) 101:8815-8820.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKAR B, MUMMIDI S, VALENTE AJ et al.: The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J. Biol. Chem. (2005) 280:26263-26277.
   PubMed Web of Science ®Google Scholar
• YOO JK, KWON H, KHIL LY et al.: IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J. Immunol. (2005) 175:8280-8286.
   PubMed Web of Science ®Google Scholar
• NOVICK D, KIM SH, FANTUZZI G et al.: Interleukin-18 binding protein: a novel modulator of the TH1 cytokine response. Immunity (1999) 10:127-136.
   PubMed Web of Science ®Google Scholar
• KIM SH, EISENSTEIN M, REZNIKOV L et al.: Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA (2000) 97:1190-1195.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA, NOVICK D, RUBINSTEIN M, LONNEMANN G: Interleukin 18 and interleukin 18 binding protein: possible role in immunosuppression of chronic renal failure. Blood Purif. (2003) 21:258-270.
   PubMed Web of Science ®Google Scholar
• PAULUKAT J, BOSMANN M, NOLD M et al.: Expression and release of IL-18 binding protein in response to IFN-γ. J. Immunol. (2001) 167:7038-7043.
   PubMed Web of Science ®Google Scholar
• MOLLER B, PAULUKAT J, NOLD M et al.: Interferon-γ induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology (2003) 42:442-445.
   PubMed Web of Science ®Google Scholar
• LOVENBERG TW, CROWE PD, LIU C et al.: Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2). J. Neuroimmunol. (1996) 70:113-122.
   PubMed Web of Science ®Google Scholar
• PARNET P, GARKA KE, BONNERT TP, DOWER SK, SIMS JE: IL-1Rrp is a novel receptor-like molecule similar to the Type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J. Biol. Chem. (1996) 271:3967-3970.
   PubMed Web of Science ®Google Scholar
• TRAJKOVIC V, SWEET MJ, XU D: T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. (2004) 15:87-95.
   PubMed Web of Science ®Google Scholar
• LECART S, LECOINTE N, SUBRAMANIAM A et al.: Activated, but not resting human TH2 cells, in contrast to TH1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur. J. Immunol. (2002) 32:2979-2987.
   PubMed Web of Science ®Google Scholar
• SHIMIZU M, MATSUDA A, YANAGISAWA K et al.: Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum. Mol. Genet. (2005) 14:2919-2927.
   PubMed Web of Science ®Google Scholar
• BRINT EK, XU D, LIU H et al.: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immun. (2004) 5:373-379.
   Google Scholar
• TAJIMA S, OSHIKAWA K, TOMINAGA S, SUGIYAMA Y: The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest (2003) 124:1206-1214.
   PubMed Web of Science ®Google Scholar
• BRUNNER M, KRENN C, ROTH G et al.: Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. (2004) 30:1468-1473.
   PubMed Web of Science ®Google Scholar
• SHIMPO M, MORROW DA, WEINBERG EO et al.: Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation (2004) 109:2186-2219.
   PubMed Web of Science ®Google Scholar
• LEUNG BP, XU D, CULSHAW S, MCINNES IB, LIEW FY: A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. (2004) 173:145-150.
   PubMed Web of Science ®Google Scholar
• THOMASSEN E, RENSHAW BR, SIMS JE: Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine (1999) 11:389-399.
   PubMed Web of Science ®Google Scholar
• WALD D, QIN J, ZHAO Z et al.: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immun.(2003) 4:920-927.
   Google Scholar
• GARLANDA C, RIVA F, POLENTARUTTI N et al.: Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl. Acad. Sci. USA (2004) 101:3522-3526.
   PubMed Web of Science ®Google Scholar
• QIN J, QIAN Y, YAO J, CUI G, LI X: SIGIRR inhibits IL-1R-and TLR4-mediated signaling through different mechanisms. J. Biol. Chem. (2005) 280:25233-25241.
   PubMed Web of Science ®Google Scholar
• CARRIE A, JUN L, BIENVENU T et al.: A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nat. Genet. (1999) 23:25-31.
   PubMed Web of Science ®Google Scholar
• BORN TL, SMITH DE, GARKA KE et al.: Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family. Delineation of a new class of IL-1R-related proteins based on signaling. J. Biol. Chem. (2000) 275:29946-29954.
   PubMed Web of Science ®Google Scholar
• JIN H, GARDNER RJ, VISWESVARAIAH R, MUNTONI F, ROBERTS RG: Two novel members of the interleukin-1 receptor gene family, one deleted in Xp22.1-Xp21.3 mental retardation. Eur. J. Hum. Genet. (2000) 8:87-94.
   PubMed Web of Science ®Google Scholar
• SANA TR, DEBETS R, TIMANS JC, BAZAN JF, KASTELEIN RA: Computational identification, cloning, and characterization of IL-1R9, a novel interleukin-1 receptor-like gene encoded over an unusually large interval of human chromosome Xq22.2-q22.3. Genomics (2000) 69:252-262.
   PubMed Web of Science ®Google Scholar
• KHAN JA, BRINT EK, O’NEILL LA, TONG L: Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J. Biol. Chem. (2004) 279:31664-31670.
   PubMed Web of Science ®Google Scholar
• BAHI N, FRIOCOURT G, CARRIE A et al.: IL1 receptor accessory protein like, a protein involved in X-linked mental retardation, interacts with Neuronal Calcium Sensor-1 and regulates exocytosis. Hum. Mol. Genet. (2003) 12:1415-1425.
   PubMed Web of Science ®Google Scholar
• COX A, CAMP NJ, NICKLIN MJH, DI GIOVINE FS, DUFF GW: An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am. J. Hum. Genet. (1998) 62:1180-1188.
   PubMed Web of Science ®Google Scholar
• DU Y, DODEL RC, EASTWOOD BJ et al.: Association of an interleukin 1 polymorphism with Alzheimer’s disease. Neurology (2000) 55:480-484.
   PubMed Web of Science ®Google Scholar
• GRIMALDI LM, CASADEI VM, FERRI C et al.: Association of early-onset Alzheimer’s disease with an interleukin-1α gene polymorphism. Ann. Neurol. (2000) 47:361-365.
   PubMed Web of Science ®Google Scholar
• GREEN EK, HARRIS JM, LEMMON H et al.: Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology (2002) 58:1566-1568.
   Google Scholar
• SERIPA D, MATERA MG, DAL FORNO G et al.: Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiol. Aging (2005) 26:455-464.
   PubMed Web of Science ®Google Scholar
• HAYES A, GREEN EK, PRITCHARD A et al.: A polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry (2004) 75:1475-1477.
   PubMed Web of Science ®Google Scholar
• GRIFFIN WS: Inflammation and neurodegenerative diseases. Am. J. Clin. Nutr. (2006) 83:470S-474S.
   PubMed Web of Science ®Google Scholar
• JOUVENNE P, CHAUDHARY A, BUCHS N et al.: Possible genetic association between interleukin-1α gene polymorphism and the severity of chronic polyarthritis. Eur. Cytokine Netw. (1999) 10:33-36.
   PubMed Web of Science ®Google Scholar
• CAMP NJ, COX A, DI GIOVINE FS et al.: Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun. (2005) 6:467-471.
   PubMed Web of Science ®Google Scholar
• KIMURA R, NISHIOKA T, SOEMANTRI A, ISHIDA T: Cis-acting effect of the IL1B C-31T polymorphism on IL-1 β mRNA expression. Genes Immun. (2004) 5:572-575.
   PubMed Web of Science ®Google Scholar
• HALL SK, PERREGAUX DG, GABEL CA et al.: Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 β protein. Arthritis Rheum. (2004) 50:1976-1983.
   PubMed Web of Science ®Google Scholar
• WANG ZC, YUNIS EJ, DE LOS SANTOS MJ et al.: T helper 1-type immunity to trophoblast antigens in women with a history of recurrent pregnancy loss is associated with polymorphism of the IL1B promoter region. Genes Immun. (2002) 3:38-42.
   PubMed Web of Science ®Google Scholar
• LICASTRO F, VEGLIA F, CHIAPPELLI M, GRIMALDI LM, MASLIAH E: A polymorphism of the interleukin-1 β gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer’s disease. Neurobiol. Aging (2004) 25:1017-1022.
   PubMed Web of Science ®Google Scholar
• CHEN H, WILKINS LM, AZIZ N et al.: Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum. Mol. Genet. (2006) 15:519-529.
   PubMed Web of Science ®Google Scholar
• WITKIN SS, GERBER S, LEDGER WJ: Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin. Infect. Dis. (2002) 34:204-209.
   PubMed Web of Science ®Google Scholar
• VIJGEN L, VAN GYSEL M, RECTOR A et al.: Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. Genes Immun. (2002) 3:400-406.
   PubMed Web of Science ®Google Scholar
• DEWBERRY RM, CROSSMAN DC, FRANCIS SE: Interleukin-1 receptor antagonist (IL-1RN) genotype modulates the replicative capacity of human endothelial cells. Circ. Res. (2003) 92:1285-1287.
   PubMed Web of Science ®Google Scholar
• REDLITZ KH, YAMSHCHIKOV VF, COMINELLI F: Differential contribution of IL-1Ra isoforms to allele-specific IL-1Ra mRNA accumulation. J. Interferon Cytokine Res. (2004) 24:253-260.
   PubMed Web of Science ®Google Scholar
• CARTER MJ, JONES S, CAMP NJ et al.: Functional correlates of the interleukin-1 receptor antagonist gene polymorphism in the colonic mucosa in ulcerative colitis. Genes Immun. (2004) 5:8-15.
   PubMed Web of Science ®Google Scholar
• LIND H, ZIENOLDDINY S, RYBERG D et al.: Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1β gene. Lung Cancer (2005) 50:285-290.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, REEVE JP, REVEILLE JD et al.: High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Arthritis Rheum. (2003) 48:2011-2018.
   PubMed Web of Science ®Google Scholar
• SMITH AJ, KEEN LJ, BILLINGHAM MJ et al.: Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: association with knee osteoarthritis. Genes Immun. (2004) 5:451-460.
   PubMed Web of Science ®Google Scholar
• TIMMS AE, CRANE AM, SIMS AM et al.: The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am. J. Hum. Genet. (2004) 75:587-595.
   PubMed Web of Science ®Google Scholar
• CHOU CT, TIMMS AE, WEI JC et al.: Replication of association of IL-1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann. Rheum. Dis. (2005) (In Press).
   Google Scholar
• SAMANI NJ, BURTON P, MANGINO M et al.: A genomewide linkage study of 1,933 families affected by premature coronary artery disease: The British Heart Foundation (BHF) Family Heart Study. Am. J. Hum. Genet. (2005) 77:1011-1020.
   PubMed Web of Science ®Google Scholar
• TIRET L, GODEFROY T, LUBOS E et al.: Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation (2005) 112:643-650.
   PubMed Web of Science ®Google Scholar
• NOVAK N, KRUSE S, POTRECK J et al.: Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. J. Allergy Clin. Immunol. (2005) 115:828-833.
   PubMed Web of Science ®Google Scholar
• IMBODEN M, NICOD L, NIETERS A et al.: The common G-allele of interleukin-18 single-nucleotide polymorphism is a genetic risk factor for atopic asthma. Clin. Exp. Allergy (2006) 36:211-218.
   PubMed Web of Science ®Google Scholar
• ARIMITSU J, HIRANO T, HIGA S et al.: IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem. Biophys. Res. Commun. (2006) 342:1413-1416.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol. (2004) 4:378-385.
   PubMed Web of Science ®Google Scholar
• ASHWELL S: Caspases: recent advances in small molecule inhibitors. Expert Opin. Ther. Patents (2001) 11:1593-1603.
   Web of Science ®Google Scholar
• LINTON SD: Caspase inhibitors: a pharmaceutical industry perspective. Curr. Top. Med. Chem. (2005) 5:1697-1717.
   PubMed Web of Science ®Google Scholar
• O’NEIL SV, WANG Y, LAUFERSWEILER MC et al.: Synthesis and evaluation of novel 8,6-fused bicyclic peptidomimetic compounds as interleukin-1β converting enzyme inhibitors. Bioorg. Med. Chem. Lett (2005) 15:5434-5438.
   PubMed Web of Science ®Google Scholar
• LAUFERSWEILER MC, WANG Y, SOPER DL et al.: Synthesis and evaluation of tricyclic pyrrolopyrimidinones as dipeptide mimetics: inhibition of interleukin-1β-converting enzyme. Bioorg. Med. Chem. Lett. (2005) 15:4322-4326.
   PubMed Web of Science ®Google Scholar
• OPPONG KA, ELLIS CD, LAUFERSWEILER MC et al.: Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1β synthesis. Bioorg. Med. Chem. Lett (2005) 15:4291-4294.
   PubMed Web of Science ®Google Scholar
• FAHR BT, O’BRIEN T, PHAM P et al.: Tethering identifies fragment that yields potent inhibitors of human caspase-1. Bioorg. Med. Chem. Lett (2006) 16:559-562.
   PubMed Web of Science ®Google Scholar
• STACK JH, BEAUMONT K, LARSEN PD et al.: IL-1-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. (2005) 175:2630-2634.
   PubMed Web of Science ®Google Scholar
• LABASI JM, PETRUSHOVA N, DONOVAN C et al.: Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. (2002) 168:6436-6445.
   PubMed Web of Science ®Google Scholar
• CHESSELL IP, HATCHER JP, BOUNTRA C et al.: Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain (2005) 114:386-396.
   PubMed Web of Science ®Google Scholar
• BAXTER A, BENT J, BOWERS K et al.: Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg. Med. Chem. Lett (2003) 13:4047-4050.
   PubMed Web of Science ®Google Scholar
• ALCARAZ L, BAXTER A, BENT J et al.: Novel P2X7 receptor antagonists. Bioorg. Med. Chem. Lett (2003) 13:4043-4046.
   PubMed Web of Science ®Google Scholar
• MERRIMAN GH, MA L, SHUM P et al.: Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15:435-438.
   PubMed Web of Science ®Google Scholar
• PERREGAUX DG, MCNIFF P, LALIBERTE R et al.: Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J. Pharmacol. Exp. Ther. (2001) 299:187-197.
   PubMed Web of Science ®Google Scholar
• LALIBERTE RE, PERREGAUX DG, HOTH LR et al.: Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1β posttranslational processing. J. Biol. Chem. (2003) 278:16567-16578.
   PubMed Web of Science ®Google Scholar
• YIN ZL, DAHLSTROM JE, LE COUTEUR DG, BOARD PG: Immunohistochemistry of omega class glutathione-S-transferase in human tissues. J. Histochem. Cytochem. (2001) 49:983-987.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA K, HIRAI H, ISHIGURO M et al.: Novel cytokine production inhibitors produced by a basidiomycete, Marasmiellus sp. J. Antibiot. (2001) 54:703-709.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA K, HIRAI H, ISHIGURO M et al.: Cytokine production inhibitors produced by a fungus, Oidiodendron griseum. J. Antibiot. (2001) 54:697-702.
   PubMed Web of Science ®Google Scholar
• MATSUDA T, AOKI T, KOSHI T, OHKUCHI M, SHIGYO H: Synthesis and bioactivities of novel 5,6-bis(4-methoxyphenyl)-2H-pyridazin-3-one derivatives: inhibitors of interleukin-1 β (IL-1β) production. Bioorg. Med. Chem. Lett (2001) 11:2373-2375.
   PubMed Web of Science ®Google Scholar
• MATSUDA T, AOKI T, OHGIYA T et al.: Synthesis and bioactivities of novel pyridazine derivatives: inhibitors of interleukin-1 β (IL-1β) production. Bioorg. Med. Chem. Lett (2001) 11:2360-2372.
   Google Scholar
• VERBRUGGEN G: Chondroprotective drugs in degenerative joint diseases. Rheumatology (2006) 45:129-138.
   PubMed Web of Science ®Google Scholar
• BESSIS N, GUERY L, MANTOVANI A et al.: The Type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur. J. Immunol. (2000) 30:867-875.
   PubMed Web of Science ®Google Scholar
• SMEETS RL, JOOSTEN LA, ARNTZ OJ et al.: Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum. (2005) 52:2202-2211.
   PubMed Web of Science ®Google Scholar
• ECONOMIDES AN, CARPENTER LR, RUDGE JS et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9:47-52.
   PubMed Web of Science ®Google Scholar
• GABAY C: IL-1 trap. Regeneron/Novartis. Curr. Opin. Invest. Drugs (2003) 4:593-597.
   PubMedGoogle Scholar
• CANNA S, GELABERT A, AKSENTIJEVICH I et al.: Treatment of 4 patients with cryopyrin-associated periodic syndromes with the long acting IL-1 inhibitor IL-1 trap. Annual Meeting European Congress of Rheumatology, European League Against Rheumatism. Vienna, Austria (2005) Abstr. OP0154.
   Google Scholar
• RECTENWALD JE, MOLDAWER LL, HUBER TS, SEEGER JM, OZAKI CK: Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation (2000) 102:1697-1702.
   PubMed Web of Science ®Google Scholar
• CHI H, MESSAS E, LEVINE RA, GRAVES DT, AMAR S: Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation (2004) 110:1678-1685.
   PubMed Web of Science ®Google Scholar
• WAEHRE T, YNDESTAD A, SMITH C et al.: Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation (2004) 109:1966-1972.
   PubMed Web of Science ®Google Scholar
• LU J, WITCHER DR, WHITE MA et al.: IL-1β epitope mapping using site-directed mutagenesis and hydrogen-deuterium exchange mass spectrometry analysis. Biochemistry (2005) 44:11106-11114.
   PubMed Web of Science ®Google Scholar
• BERTIN-MAGHIT SM, CAPINI CJ, BESSIS N et al.: Improvement of collagen-induced arthritis by active immunization against murine IL-1β peptides designed by molecular modelling. Vaccine (2005) 23:4228-4235.
   PubMed Web of Science ®Google Scholar
• FLEISCHMANN R, STERN R, IQBAL I: Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. (2004) 4:1333-1344.
   PubMed Web of Science ®Google Scholar
• BUCH MH, BINGHAM SJ, SETO Y et al.: Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade. Arthritis Rheum. (2004) 50:725-728.
   PubMed Web of Science ®Google Scholar
• FLEISHMANN RM: Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-α agents. Clin. Exp. Rheumatol. (2002) 20:S35-S41.
   Google Scholar
• VERBSKY JW, WHITE AJ: Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. (2004) 31:2071-2075.
   PubMed Web of Science ®Google Scholar
• PASCUAL V, ALLANTAZ F, ARCE E, PUNARO M, BANCHEREAU J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. (2005) 201:1479-1486.
   PubMed Web of Science ®Google Scholar
• FITZGERALD AA, LECLERCQ SA, YAN A, HOMIK JE, DINARELLO CA: Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. (2005) 52:1794-1803.
   PubMed Web of Science ®Google Scholar
• HAWKINS PN, LACHMANN HJ, AGANNA E, MCDERMOTT MF: Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. (2004) 50:607-612.
   PubMed Web of Science ®Google Scholar
• LOVELL DJ, BOWYER SL: Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal onset multisystem inflammatory disease. Arthritis Rheum. (2005) 52:1283-1286.
   PubMed Web of Science ®Google Scholar
• DIERSELHUIS MP, FRENKEL J, WULFFRAAT NM, BOELENS JJ: Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (2005) 44:406-408.
   PubMed Web of Science ®Google Scholar
• EMSLEY HC, SMITH CJ, GEORGIOU RF et al.: A randomised Phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry (2005) 76:1366-1372.
   PubMed Web of Science ®Google Scholar
• CHEVALIER X, GIRAUDEAU B, CONROZIER T et al.: Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol. (2005) 32:1317-1323.
   PubMed Web of Science ®Google Scholar
• CHEVALIER X, GOUPILLE P, BEAULIEU AD et al.: Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of anakinra (KineretR) in patients with osteoarthritis of the knee. ACR Meeting (2005) Abstract 1339/115.
   Google Scholar
• FRISBIE DD, GHIVIZZANI SC, ROBBINS PD, EVANS CH, MCILWRAITH CW: Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther. (2002) 9:12-20.
   PubMed Web of Science ®Google Scholar
• HAUPT JL, FRISBIE DD, MCILWRAITH CW et al.: Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J. Orthop. Res. (2005) 23:118-126.
   PubMed Web of Science ®Google Scholar
• EVANS CH, ROBBINS PD, GHIVIZZANI SC et al.: Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc. Natl. Acad. Sci. USA (2005) 102:8698-8703.
   PubMed Web of Science ®Google Scholar
• LE MAITRE CL, FREEMONT AJ, HOYLAND JA: A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration. Int. J. Exp. Pathol. (2006) 87:17-28.
   PubMed Web of Science ®Google Scholar
• MOORE EE, BENDELE AM, THOMPSON DL et al.: Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage (2005) 13:623-631.
   PubMed Web of Science ®Google Scholar
• NESIC O, XU GY, MCADOO D et al.: IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J. Neurotrauma (2001) 18:947-956.
   PubMed Web of Science ®Google Scholar
• MAURY CP, LILJESTROM M, LAIHO K et al.: Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1β-511 promoter gene and raised levels of interleukin-1β and interleukin-18. J. Intern. Med. (2004) 256:145-152.
   PubMed Web of Science ®Google Scholar
• FREDERICKS ZL, FORTE C, CAPUANO IV et al.: Identification of potent human anti-IL-1RI antagonist antibodies. Protein Engl. Des. Sel. (2004) 17:95-106.
   PubMed Web of Science ®Google Scholar
• DAYER JM, MOLNARFI N, BURGER D: From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation? Expert Opin. Biol. Ther. (2005) 5:S83-S96.
   PubMed Web of Science ®Google Scholar
• BURNS K, JANSSENS S, BRISSONI B et al.: Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. (2003) 197:263-268.
   PubMed Web of Science ®Google Scholar
• BARTFAI T, BEHRENS MM, GAIDAROVA S et al.: A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. USA (2003) 100:7971-7976.
   PubMed Web of Science ®Google Scholar
• LOIARRO M, SETTE C, GALLO G et al.: Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-κB. J. Biol. Chem. (2005) 280:15809-15814.
   PubMed Web of Science ®Google Scholar
• LI C, ZIENKIEWICZ J, HAWIGER J: Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1β signaling pathway. J. Biol. Chem. (2005) 280:26152-26159.
   PubMed Web of Science ®Google Scholar
• MEDVEDEV AE, THOMAS K, AWOMOYI A et al.: Cutting edge: expression of IL-1 receptor-associated kinase-4 (IRAK-4) proteins with mutations identified in a patient with recurrent bacterial infections alters normal IRAK-4 interaction with components of the IL-1 receptor complex. J. Immunol. (2005) 174:6587-6591.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI T, WALSH MC, CHOI Y: The role of TRAF6 in signal transduction and the immune response. Microbes Infect. (2004) 6:1333-1338.
   PubMed Web of Science ®Google Scholar
• KARIN M, YAMAMOTO Y, WANG QM: The IKK NF-κ B system: a treasure trove for drug development. Nat. Rev. Drug Discov. (2004) 3:17-26.
   PubMed Web of Science ®Google Scholar
• COISH PDG, WICKENS PL, LOWINGER TB: Small molecule inhibitors of IKK kinase activity. Expert Opin. Ther. Patents (2006) 16:1-12.
   Web of Science ®Google Scholar
• DOMINGUEZ C, TAMAYO N, ZHANG D: p38 Inhibitors: beyond pyridinylimidazoles. Expert Opin. Ther. Patents (2005) 15:801-816.
   Web of Science ®Google Scholar
• ZHU M, XU X, LIU H et al.: Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant. J. Med. Microbiol. (2003) 52:223-228.
   PubMed Web of Science ®Google Scholar
• LIU B, MORI I, HOSSAIN MJ et al.: Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J. Gen. Virol. (2004) 85:423-428.
   PubMed Web of Science ®Google Scholar
• VAN DER SLUIJS KF, VAN ELDEN LJ, ARENS R et al.: Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza A virus. Immunology (2005) 114:112-120.
   PubMed Web of Science ®Google Scholar
• CUSUMANO V, MIDIRI A, CUSUMANO VV et al.: Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates. Infect. Immun. (2004) 72:295-300.
   PubMed Web of Science ®Google Scholar
• GOLAB J, STOKLOSA T: Technology evaluation: SB-485232, GlaxoSmithKline. Curr. Opin. Mol. Ther. (2005) 7:85-93.
   PubMed Web of Science ®Google Scholar
• LEWIS N, GOLLOB J, COHEN R et al.: Phase I dose escalation study to assess tolerability and pharmacokinetics of recombinant human IL-18 (rhIL-18) administered as fourteen daily subcutaneous injections in patients with solid tumors. J. Clin. Oncol. (2004) 22:Abstr. 2591.
   Google Scholar
• ROBERTSON MJ, MIER J, LOGAN T et al.: Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors. J. Clin. Oncol. (2004) 22:Abstr. 2553.
   Google Scholar
• MARSHALL DJ, RUDNICK KA, MCCARTHY SG et al.: Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine (2005) 24:244-253.
   PubMed Web of Science ®Google Scholar
• WIENHOLD D, ARMENGOL E, MARQUARDT A et al.: Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination. Vet. Res. (2005) 36:571-587.
   PubMed Web of Science ®Google Scholar
• LEE KA, CHO KJ, KIM SH et al.: IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response. Cancer Lett. (2005) 229:261-270.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO Y, KATO Z, MATSUKUMA E et al.: Generation of highly stable IL-18 based on a ligand-receptor complex structure. Biochem. Biophys. Res. Commun. (2004) 317:181-186.
   PubMed Web of Science ®Google Scholar
• FELDERHOFF-MUESER U, SCHMIDT OI, OBERHOLZER A, BUHRER C, STAHEL PF: IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci. (2005) 28:487-493.
   PubMed Web of Science ®Google Scholar
• MCINNES IB, LIEW FY, GRACIE JA: Interleukin-18: a therapeutic target in rheumatoid arthritis? Arthritis Res. Ther. (2005) 7:38-41.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: Targeting interleukin 18 with interleukin 18 binding protein. Ann. Rheum. Dis. (2000) 59S1:17-20.
   Google Scholar
• BANDA NK, VONDRACEK A, KRAUS D et al.: Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol. (2003) 170:2100-2105.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA, FANTUZZI G: Interleukin-18 and host defense against infection. J. Infect. Dis. (2003) 187:S370-S384.
   PubMed Web of Science ®Google Scholar
• REMICK DG, BOLGOS GE, SIDDIQUI J: Inflammatory status in sepsis alters efficacy of interleukin-18 binding protein therapy. Crit. Care Med. (2003) 31:2096-2101.
   PubMed Web of Science ®Google Scholar
• PLITZ T, SAINT-MEZARD P, SATHO M et al.: IL-18 binding protein protects against contact hypersensitivity. J. Immunol. (2003) 171:1164-1171.
   PubMed Web of Science ®Google Scholar
• REZNIKOV LL, KIM SH, ZHOU L et al.: The combination of soluble IL-18Rα and IL-18Rβ chains inhibits IL-18-induced IFN-γ. J. Interferon Cytokine Res. (2002) 22:593-601.
   PubMed Web of Science ®Google Scholar
• PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. (2001) 108:1825-1832.
   PubMed Web of Science ®Google Scholar
• SIEGMUND B, FANTUZZI G, RIEDER F et al.: Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281:R1264-R1273.
   PubMed Web of Science ®Google Scholar
• YU S, CHEN Z, MIX E et al.: Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive TH1 responses to peripheral myelin antigen. J. Neuropathol. Exp. Neurol. (2002) 61:614-622.
   PubMed Web of Science ®Google Scholar
• HAMASAKI T, HASHIGUCHI S, ITO Y et al.: Human anti-human IL-18 antibody recognizing the IL-18-binding site 3 with IL-18 signaling blocking activity. J. Biochem. (2005) 138:433-442.
   PubMed Web of Science ®Google Scholar
• STARUCH MJ, WOOD DD: The adjuvanticity of interleukin-1 in vivo. J. Immunol. (1983) 130:2191-2194.
   PubMed Web of Science ®Google Scholar
• MARTINON F, AGOSTINI L, MEYLAN E, TSCHOPP J: Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. (2004) 14:1929-1934.
   PubMed Web of Science ®Google Scholar
• HOLLIGER P, HUDSON PJ: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. (2005) 23:1626-1636.
   Google Scholar
• ROSES AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. (2004) 5:645-656.
   PubMed Web of Science ®Google Scholar
• WOLDBAEK PR, SANDE JB, STROMME TA et al.: Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am. J. Physiol. Heart Circ. Physiol. (2005) 289:H708-H714.
   PubMed Web of Science ®Google Scholar
• REUTER BK, PIZARRO TT: Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur. J. Immunol. (2004) 34:2347-2355.
   PubMed Web of Science ®Google Scholar
• SIMS J, TOWNE J, BLUMBERG H: Eleven IL-1 family members in inflammatory skin disease. Ernst Schering Res. Found. Workshop (2006) 56:187-191.
   PubMedGoogle Scholar
• PICARD C, PUEL A, BONNET M, AL E: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science (2003) 299:2076-2079.
   PubMed Web of Science ®Google Scholar
• MILLER LS, O’CONNELL RM, GUTIERREZ MA et al.: MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity (2006) 24:79-91.
   PubMed Web of Science ®Google Scholar